These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 28437234)

  • 1. Poliovirus vaccination during the endgame: insights from integrated modeling.
    Duintjer Tebbens RJ; Thompson KM
    Expert Rev Vaccines; 2017 Jun; 16(6):577-586. PubMed ID: 28437234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame.
    Duintjer Tebbens RJ; Pallansch MA; Wassilak SG; Cochi SL; Thompson KM
    BMC Infect Dis; 2016 Mar; 16():137. PubMed ID: 27009272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine.
    Duintjer Tebbens RJ; Thompson KM
    Expert Rev Vaccines; 2018 Aug; 17(8):739-751. PubMed ID: 30056767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eradicating polio: how the world's pediatricians can help stop this crippling illness forever.
    Orenstein WA;
    Pediatrics; 2015 Jan; 135(1):196-202. PubMed ID: 25548328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Updated Characterization of Post-OPV Cessation Risks: Lessons from 2019 Serotype 2 Outbreaks and Implications for the Probability of OPV Restart.
    Kalkowska DA; Pallansch MA; Cochi SL; Kovacs SD; Wassilak SGF; Thompson KM
    Risk Anal; 2021 Feb; 41(2):320-328. PubMed ID: 32632925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential benefits of a new poliovirus vaccine for long-term poliovirus risk management.
    Duintjer Tebbens RJ; Thompson KM
    Future Microbiol; 2016 Dec; 11():1549-1561. PubMed ID: 27831742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The new polio eradication end game: rationale and supporting evidence.
    Sutter RW; Platt L; Mach O; Jafari H; Aylward RB
    J Infect Dis; 2014 Nov; 210 Suppl 1():S434-8. PubMed ID: 25316865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs.
    Duintjer Tebbens RJ; Thompson KM
    BMC Infect Dis; 2015 Sep; 15():390. PubMed ID: 26404780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expected Implications of Globally Coordinated Cessation of Serotype 3 Oral Poliovirus Vaccine (OPV) Before Serotype 1 OPV.
    Kalkowska DA; Thompson KM
    Risk Anal; 2021 Feb; 41(2):312-319. PubMed ID: 32936466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Logistical challenges and assumptions for modeling the failure of global cessation of oral poliovirus vaccine (OPV).
    Thompson KM; Kalkowska DA
    Expert Rev Vaccines; 2019 Jul; 18(7):725-736. PubMed ID: 31248293
    [No Abstract]   [Full Text] [Related]  

  • 11. Decision analysis in planning for a polio outbreak in the United States.
    Jenkins PC; Modlin JF
    Pediatrics; 2006 Aug; 118(2):611-8. PubMed ID: 16882814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The case for cooperation in managing and maintaining the end of poliomyelitis: stockpile needs and coordinated OPV cessation.
    Thompson KM; Duintjer Tebbens RJ
    Medscape J Med; 2008; 10(8):190. PubMed ID: 18924642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation.
    Duintjer Tebbens RJ; Thompson KM
    J Infect Dis; 2014 Nov; 210 Suppl 1():S485-97. PubMed ID: 25316871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lessons From Globally Coordinated Cessation of Serotype 2 Oral Poliovirus Vaccine for the Remaining Serotypes.
    Thompson KM; Duintjer Tebbens RJ
    J Infect Dis; 2017 Jul; 216(suppl_1):S168-S175. PubMed ID: 28838198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polio endgame: the global introduction of inactivated polio vaccine.
    Patel M; Zipursky S; Orenstein W; Garon J; Zaffran M
    Expert Rev Vaccines; 2015 May; 14(5):749-62. PubMed ID: 25597843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation.
    Duintjer Tebbens RJ; Hampton LM; Thompson KM
    BMC Infect Dis; 2016 May; 16():231. PubMed ID: 27230071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. National choices related to inactivated poliovirus vaccine, innovation and the endgame of global polio eradication.
    Thompson KM; Duintjer Tebbens RJ
    Expert Rev Vaccines; 2014 Feb; 13(2):221-34. PubMed ID: 24308581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modeling the dynamics of oral poliovirus vaccine cessation.
    Thompson KM; Duintjer Tebbens RJ
    J Infect Dis; 2014 Nov; 210 Suppl 1():S475-84. PubMed ID: 25316870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coverage estimates and patterns of inactivated poliovirus vaccine (IPV) use prior to and during the polio eradication endgame, Jinan City, China, 2010-2015.
    Chang C; Zhang J; Zhou J; Cao R; Song K; Liu C; Zhang X; Geng X; Liu X; Li C
    Hum Vaccin Immunother; 2016 Nov; 12(11):2749-2752. PubMed ID: 27437792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reflections on Modeling Poliovirus Transmission and the Polio Eradication Endgame.
    Thompson KM; Kalkowska DA
    Risk Anal; 2021 Feb; 41(2):229-247. PubMed ID: 32339327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.